Clinical Trial Update: Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy study of Serostim for HIV-associated adipose redistribution syndrome has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome

Drugs mentioned

• SEROSTIM (somatropin)

Snippet

Sponsor: EMD Serono | Conditions: Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2010-06-23